Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues

Chinese Journal of Cancer

Volumn 28, Issue 9, 2009, Pages

  Yuan, Shu Qiang ^a   Zhou, Zhi Wei ^a   Liang, Yong Ju ^a   Fu, Li Wu ^a   Chen, Gong ^a   Qiu, Hai Bo ^a   Zhang, Li Yi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ABCG2; Colorectal cancer; Drug sensitivity test; MDR1; MRP1; Multidrug resistance; Tissue culture

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASSAY; CANCER INHIBITION; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; CORRELATION ANALYSIS; DRUG INHIBITION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HISTOCULTURE DRUG RESPONSE ASSAY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE GENE; ONCOGENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS; SENSITIVITY ANALYSIS;

EID: 79955754607     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.008.10787     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J], CA Cancer J Clin, 2007, 57(1): 43-66.
2. Wu F. Molecules or gene indices for predicting the therapeutic effect of chemotherapy for intestinal carcinoma [J]. Ai Zheng Jin Zhan, 2006, 4(3): 248-254. [in Chinese]
3. Technology Evaluation Center Assessment Program. Chemotherapy sensitivity and resistance assays [J]. Tecnologica MAP Suppl, 2002, 17(12): 1-40.
4. Gutmann H, Fricker G, Török M, et al. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake [J], Pharm Res, 1999, 16(3): 402-407.
5. Grant CE, Kurz EU, Cole SP, et al. Analysis of the Intron-Exon Organization of the Human Multidrug-Resistance Protein Gene (MRP) and Alternative Splicing of Its mRNA [J]. Genomics, 1997, 45(2): 368-378.
6. Deichmann M, Thome M, Egner U, et al. The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin [J]. J Cutan Pathol, 2005, 32(7): 467-473.
7. Chua YJ, Zalcberg JR. Progress and challenges in the adjuvant treatment of stage II and III colon cancers [J]. Expert Rev Anticancer Ther, 2008, 8(4): 595-604.
8. Ahmed FE. Molecular markers that predict response to colon cancer therapy [J]. Expert Rev Mol Diagn, 2005, 5(3): 353-375.
9. Ochiai T, Nishimura K, Noguchi H, et al. Evaluation of 5-fluorouracil applicability by multi-point collagen gel droplet embedded drug sensitivity test [J]. Anticancer Drugs, 2007, 18(1): 17-21.
10. Vescio RA, Redfern CH, Nelson TJ, et al. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture [J]. Proc Natl Acad Sci, 1987, 84(14): 5029-5033.
11. Liang YJ, Zhou XX, Pan QC, et al. The in vitro drug response test for single drug administration and combinatory drug administration in ovarian cancer [J]. Zhong Liu, 1999, 18(6): 742-743. [in Chinese]
12. Liang YJ, Feng GK, Fan QC, et al. Drug sensitivity tests for ovarian cancer using sigle or combined drugs in vitro [J]. Ai Zheng, 1999, 18(6): 742-743.[in Chinese]
13. Furukawa T, Kubota T, Hoffman RM. Clinical applications of histoculture response assay [J]. Clin Cancer Res, 1997, 1 (1): 305-311.
14. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate [J]. J Clin Oncol, 10(6): 896-903.
15. de Gramont A, Bosset FJ, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study [J]. J Clin Oncol, 1997, 15(2): 808-815.
16. Kemeny N, Israel K, Nied Zwiecki D, et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer [J]. J Clin Oncol, 1990, 8(2): 313-318.
17. Ramanathan RK, Picus J, Raftopoulos H, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer [J]. Cancer Chemother Pharmacol, 2008, 61(3): 453-458.
18. Gargano L, Menichetti ET, Marcellini M, et al. Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer [J]. Chemotherapy, 2001, 47(6): 438-443.
19. Caliò E, Seminara P, Aronne T, et al. In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer [J]. Chemotherapy, 2001, 47(6): 430-437.
20. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity [J]. Pharmacogenomics, 2004, 5(7): 835-843.
21. Monden N, Abe S, Hishikawa Y. The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy [J]. Int Surg Investig, 1999, 1(1): 3-10.
22. Song SM, Mao YR, Zhou JL, et al. The expression of p-glycoprotein in hepatic lesion and its clinical significance [J]. Zhong Liu Fang Zhi Yan Jiu, 1999, 26(2): 96. [in Chinese]
23. Lacueva J, Perez-Ramos M, Soto JL, et al. Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR [J]. Histopathology, 2005, 46(4): 389-395.
24. Nooter K, Brutel de la Riviere G, Look MP, et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer [J]. Br J Cancer, 1997, 76(4): 486-493.
25. Endo K, Maehara Y, Kusumoto T, et al. Expression of multidrug resistance associated protein (MRP) and chemosensitivity in human gastric cancer [J]. Int J Cancer, 1996, 68(3): 372-377.
26. Salud A, Porcel JM, Raikundalia B, et al. Prognostic significance of DNA ploidy, S-phase fraction, and p-glycoproteinexpression in colorectal cancer [J]. J Surg Oncol, 1999, 72(3): 167-174.
27. Jiang XY, Ma LN. Quantitative measurement of MDRI-mRNA in primary intestinal carcinoma and its clinical significance [J]. Zhong Guo Shi Yan Zhen Duan Xue, 2000, 4(3): 122-124. [in Chinese]
28. Gui X, Liu HM, He J, et. al. The expression of MRP and LRP in human intestinal carcinoma tissues and its clinical significance [J]. Zhong Liu Fang Zhi Yan Jiu, 2005, 32(8): 499-501. [in Chinese]
29. Lin Y, Lin XP. The expression of MRP in colon cancer tissues and its significance [J]. Fujian Yi Yao Za Zhi, 2003, 25(5): 76-77. [in Chinese]
30. Yao F, Jin F, Fan H. The expressions of multi-drug resistance genes such as P-gp, MRP, Topo II-mRNA in intestinal carcinoma and normal tissues [J]. Shi Yong Zhong Liu Xue Za Zhi, 2003, 17(4): 260-261. [in Chinese]
31. Mori M, Mimori K, Shiraishi T, et al. Motility related protein 1(MRP1 CD9) expression in colon cancer [J]. Clin Cancer Res, 1998, 4(6): 1507-1510.
32. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy [J]. Pathol Res Pract, 1996, 192(7): 768-780.
33. Zhang ZL. The clinical significance and measuring technique for multi-drug resistance genes [J]. Zhong Liu Fang Zhi Yan Jiu, 1999, 26(6): 476-479. [in Chinese]
34. Yague E, Armes Ila AL, Harrison G, et al. P-glycoprotein(MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA: stabilization and translational initiation [J]. J Biol Chem, 2003, 278(12): 10344-10352.
35. Doyle A, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2) [J]. Oncogene, 2003, 22(47): 7340-7358.
36. Gupta N, Martin PM, Miyauchi S, et al. Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer [J]. Biochem Biophys Res Commun, 2006, 343(2): 571-577.